Discontinued — last reported Q2 '23
U. S. Healthcare Solutions — Operating Income
Cencora U. S. Healthcare Solutions — Operating Income decreased by 16.0% to $635.18M in Q2 2023 compared to the prior quarter. Year-over-year, this metric grew by 9.5%, from $579.93M to $635.18M. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
An increase suggests improved pricing power, higher distribution volumes, or better operational cost management within the domestic pharmaceutical supply chain. A decrease may indicate margin compression due to competitive pricing pressures, changes in product mix toward lower-margin generics, or increased logistics and operating expenses.
Detailed definition
This metric represents the operating profit generated by the U.S. Healthcare Solutions segment, which encompasses the co...
Peer comparison
This is highly comparable to the core pharmaceutical distribution segment operating income reported by other major industry wholesalers like McKesson and Cardinal Health.
cor_segment_u_s_healthcare_solutions_operating_incomeHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | |
|---|---|---|---|---|---|---|---|---|---|
| Value | $529.79M | $507.49M | $569.09M | $729.54M | $579.93M | $578.42M | $572.42M | $756.14M | $635.18M |
| QoQ Change | — | -4.2% | +12.1% | +28.2% | -20.5% | -0.3% | -1.0% | +32.1% | -16.0% |
| YoY Change | — | — | — | — | +9.5% | +14.0% | +0.6% | +3.6% | +9.5% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Cencora's u. s. healthcare solutions — operating income?
- Cencora (COR) reported u. s. healthcare solutions — operating income of $635.18M in Q2 2023.
- How has Cencora's u. s. healthcare solutions — operating income changed year-over-year?
- Cencora's u. s. healthcare solutions — operating income increased by 9.5% year-over-year, from $579.93M to $635.18M.
- What does u. s. healthcare solutions — operating income mean?
- The operating profit earned from the company's core pharmaceutical distribution and wholesale business in the United States.